跳至主要内容
临床试验/NCT06320379
NCT06320379招募中不适用

Evaluating Changes in Quality of Life and Digestion in Functional Dyspepsia in Adults

National University of Natural Medicine2 个研究点 分布在 1 个国家目标入组 64 人开始时间: 2023年3月15日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
64
试验地点
2
主要终点
Protein Assimilation

研究概览

简要总结

The purpose of this study is to determine the effects of a readily available dietary supplement on quality of life and digestion in adults with functional dyspepsia.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Other
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
18 Years 至 70 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • ● Adults 18-70 years of age (inclusive)
  • A self-reported history of symptoms consistent with Functional Dyspepsia (per Rome IV criteria - See Telephone Screening), and self-reported absence of organic disease and infection (e.g., Helicobacter pylori) with or without a formal diagnosis by a healthcare professional.
  • Adults ≥ 60 years of age must have had a normal upper gastrointestinal endoscopy
  • Willing to be randomized to take a daily dietary supplement or placebo over the 4-week study period
  • Not taken antibiotics or other drugs prescribed specifically for symptoms consistent with Functional Dyspepsia (per Rome IV criteria) for a period up to 1 month before the beginning of the study.
  • On a stable dose of all medications prior to study entry (i.e., consistent dose for a minimum of three months)
  • On a stable dose of dietary supplements for at least one month prior to enrollment
  • Willing to avoid initiation of new supplements and/or medications unless otherwise indicated by a healthcare professional
  • Able to communicate via email, complete computer-administered questionnaires, and to read and write in English.
  • Approved to be eligible for study participation at the discretion of the Principal Investigators, after review of the Formal Eligibility Screen results.
  • Non-smokers (including tobacco and cannabis products, combusted or vaporized)
  • Willing to provide written informed consent and to follow the required protocol

排除标准

  • ● A self-reported history of peptic and/or duodenal ulcers, H. pylori infection, gastroesophageal reflux disease (GERD) explained by upper endoscopy, irritable bowel syndrome (IBS), and other chronic GI disorders.
  • Positive fecal occult blood test (FOBT) at the clinical screening visit
  • Current use of digestive enzyme and/or betaine HCL-containing dietary supplements
  • Current use of prescribed proton-pump inhibitors
  • Current use of drugs that interfere with gastrointestinal motility, including prokinetic agents.
  • History of previous abdominal surgery, including gastric surgery, excluding appendectomy.
  • Individuals with chronic kidney or liver disease, cancer, colorectal disease and/or other rare disorders that at the discretion of the PI or Clinical Investigator may impact their safety or confound trial results
  • Current involvement or within 14 days prior to screening of a significant diet or weight loss program (such as NutriSystem, Jenny Craig, Atkin's or other low-carb diet programs) or very low-calorie liquid diet programs (such as Optifast, Medifast, and/or HMR)
  • Hospitalization (for any reason other than a scheduled medical procedure unrelated to Functional Dyspepsia) within 3 months prior to screening
  • Malignancy within the last 5 years (with the exception of basal cell carcinoma, squamous cell carcinoma, and/or carcinoma in situ of the cervix)
  • Intake of ≥ 2 standardized alcohol-containing beverages per day, 14 per week, or ≥4 in any single day within the past 14 days.
  • Individuals who do not consume, or are allergic to, animal products
  • Smoking tobacco or nicotine products (combusted or vaporized)
  • Use of illicit drugs/substances (such as but not limited to cocaine, phencyclidine (PCP), and methamphetamine) within 14 days of screening
  • Currently participating in another interventional research study, or participated in another interventional research study within 14 days of screening

结局指标

主要结局

Protein Assimilation

时间窗: Week 4

Concentrations of Amino Acids in Blood

次要结局

  • Mineral concentrations in blood(Week 4)
  • Patient Reported Outcomes Measurement Information System (PROMIS)-29 Physical Function Subscale(Week 4)
  • Leeds Dyspepsia Questionnaire(Week 4)
  • Fat-soluble vitamin concentration in blood(Baseline)
  • Fat-soluble vitamins(Week 4)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Ryan Bradley

Director of Research

National University of Natural Medicine

研究点 (2)

Loading locations...

相似试验